Abstract
The aims were to investigate the feasibility of imatinib mesylate (IM) discontinuation in chronic myeloid leukemia patients who were initially treated with IM and achieved complete molecular response (CMR). Fourteen patients were included. Ten were relapsed within 9.5. months after discontinuation of IM. All 7 patients with high Sokal risk were relapsed. The probability of CMR persistence at 1-year was 28.6%. All relapsed patients were still responsive to IM. A high Sokal risk and delayed acquisition of CMR were associated with relapse. IM discontinuation in patients achieved CMR after treatment with front-line IM might be feasible. Further studies are warranted.
| Original language | English |
|---|---|
| Pages (from-to) | 689-693 |
| Number of pages | 5 |
| Journal | Leukemia Research |
| Volume | 36 |
| Issue number | 6 |
| DOIs | |
| State | Published - 2012.06 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Chronic myeloid leukemia
- Complete molecular response
- Imatinib mesylate
- Real-time quantitative polymerase chain reaction
Quacquarelli Symonds(QS) Subject Topics
- Medicine
- Biological Sciences
Fingerprint
Dive into the research topics of 'Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver